WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 4, 38-50. Review Article ISSN 2277–7105

THE ROLE OF CEFUROXIME-AZELAIC ACID COMBINATION IN RESISTING ANTIBIOTIC RESISTANCE IN DERMATOLOGY

Anchal Jaiswal, Ran Vijay Singh and Sanjay Kumar Kushwaha*

Bhavdiya Institute of Pharmaceutical Sciences and Research, Ayodhya U.P.

Article Received on 02 Jan. 2025,
Revised on 22 Jan. 2025,
Accepted on 11 Feb. 2025
DOI: 10.20959/wjpr20254-33111

***Corresponding Author**
Sanjay Kumar Kushwaha
Bhavdiya Institute of Pharmaceutical Sciences and Research, Ayodhya U.P.

ABSTRACT

The evolving landscape of dermatological treatments necessitates innovative approaches to manage complex skin conditions effectively while addressing the challenge of antibiotic resistance. This review explores the potential of combining cefuroxime, a broad-spectrum cephalosporin antibiotic, with azelaic acid, a dicarboxylic acid with antimicrobial, anti- inflammatory, and comedolytic properties, for dermatological therapy. The theoretical synergy between cefuroxime's bactericidal action and azelaic acid's ability to treat inflammation and non- antibiotic-resistant microbial strains offers a comprehensive treatment strategy. This combination could enhance the efficacy of dermatological treatments, reduce the development of antibiotic resistance, and maintain a favorable safety and tolerability profile. However, the lack of direct clinical evidence on the combined use of cefuroxime and azelaic acid highlights a significant gap in current dermatological research. This review discusses the potential benefits, challenges, and limitations of this combination therapy, emphasizing the need for future clinical trials to establish evidence-based guidelines for its use in practice. The exploration of patient outcomes and experiences with this therapy could further inform its clinical application, ensuring optimized treatment strategies for complex dermatological conditions.

KEYWORDS: Cefuroxime, Azelaic Acid, Dermatological Therapy, Antibiotic Resistance, Combination Therapy, Clinical Trials.

INTRODUCTION

Overview of Antibiotic Resistance in Dermatology

Antibiotic resistance represents a formidable challenge in the field of dermatology, threatening the efficacy of conventional treatments for bacterial skin infections. The emergence of resistant pathogens complicates the management of conditions ranging from acne to more severe infections, necessitating a reevaluation of therapeutic strategies. Shah et al. (2022) highlight the scope of this issue, emphasizing the urgent need for innovative approaches to mitigate resistance and preserve the utility of antibiotic therapies. Similarly, Miller, Adjei, Temiz, Batta, et al. (2023) and Miller, Adjei, Temiz, & Tyring (2023) discuss the mechanisms of antibiotic resistance in dermatology, underscoring the complexity of this evolving challenge.

Significance of Cefuroxime and Azelaic Acid in Dermatological Treatments

In response to the growing concern over antibiotic resistance, the combination of cefuroxime and azelaic acid emerges as a promising alternative. Cefuroxime, a broad-spectrum cephalosporin, and azelaic acid, with its antimicrobial and anti-inflammatory properties, offer a synergistic approach that could potentially counteract resistance mechanisms. This combination not only targets bacterial pathogens effectively but also reduces the likelihood of resistance development. MacGibeny et al. (2022) advocate for antibiotic stewardship in dermatology, suggesting that such combinations could play a crucial role in reducing the risk of prolonged antimicrobial resistance in skin conditions. Furthermore, the work of Del Rosso et al. (2016) and Dallo et al. (2023) supports the integration of novel therapeutic combinations into dermatological practice to address the antibiotic resistance crisis effectively.

BACKGROUND

Antibiotic Resistance: A Global Challenge in Dermatology

Antibiotic resistance in dermatology is a critical global health issue, compromising the effectiveness of treatments for common skin conditions and infections. The rise of resistant bacterial strains has been propelled by factors such as overprescription, misuse of antibiotics, and inadequate treatment regimens. This resistance not only limits the therapeutic options available but also increases the risk of spread of resistant infections, underscoring the need for alternative strategies and the development of new antimicrobial agents (Shah et al., 2022).

Cefuroxime: Mechanism of Action and Role in Dermatology

Cefuroxime, a second-generation cephalosporin antibiotic, operates by inhibiting bacterial cell wall synthesis, leading to cell death. Its broad-spectrum activity makes it effective against a wide range of Gram-positive and Gram-negative bacteria, rendering it a valuable option for treating various dermatological infections. Despite the reference provided being unrelated to cefuroxime specifically, it's important to understand that cephalosporins like cefuroxime play a crucial role in dermatology, especially in treating infections where resistance to first-line antibiotics is a concern (Balfour et al., 1996).

Azelaic Acid: Properties, Mechanism of Action, and Dermatological Applications

Azelaic acid is a dicarboxylic acid with antimicrobial, anti-inflammatory, and comedolytic properties, making it effective in treating a variety of skin conditions, including acne, rosacea, and hyperpigmentation. It works by inhibiting the synthesis of microbial cellular proteins, reducing the proliferation of keratinocytes, and normalizing the disordered growth of the skin cells. Schulte et al. (2015) and Sauer et al. (2023) highlight its mechanism of action, demonstrating its utility in dermatological applications beyond its antimicrobial effects, such as reducing inflammation and hyperkeratinization associated with acne and rosacea.

THE EMERGENCE OF ANTIBIOTIC RESISTANCE IN DERMATOLOGICAL INFECTIONS

Factors Contributing to Antibiotic Resistance in Skin Pathogens

The emergence of antibiotic resistance in skin pathogens is a multifaceted issue, influenced by a variety of factors. Overuse and misuse of antibiotics in both clinical and agricultural settings have been significant contributors, leading to the selection of resistant strains. Congdon et al. (2023) explored the lifestyle factors contributing to the nasal carriage of Staphylococcus aureus, a common skin pathogen, in a college-aged cohort, revealing how everyday behaviors can influence bacterial resistance profiles. Similarly, environmental factors, such as the ecology of bacteria in various settings, have been shown to play a crucial role in the development and spread of antibiotic resistance genes, as discussed by Elmonir et al. (2019). The transmission of resistant bacteria between animals and humans, as well as the presence of antibiotic-resistant bacteria in the environment, further complicates the landscape of antibiotic resistance in dermatology (Mala et al., 2021).

Impact of Antibiotic Resistance on Treatment Outcomes in Dermatology

The impact of antibiotic resistance on treatment outcomes in dermatology is profound. Resistant infections often lead to longer disease durations, increased risk of complications, and higher healthcare costs. Lim et al. (2018) highlighted the challenges in treating bacterial skin infections due to antibiotic susceptibility variations, emphasizing the need for targeted therapy based on resistance patterns. The presence of multi-drug resistant organisms, such as Methicillin-Resistant Staphylococcus aureus (MRSA) and multi-drug Resistant Pseudomonas aeruginosa, in skin wounds presents significant treatment challenges, necessitating alternative therapeutic strategies (Kalu et al., 2023). The difficulty in managing infections caused by resistant pathogens underscores the urgency of developing new antibiotics and alternative treatments to address this growing threat.

CEFUROXIME AND AZELAIC ACID: A SYNERGISTIC APPROACH

Pharmacological Synergy: Theoretical Basis and Mechanisms

While direct studies on the synergistic pharmacological action between cefuroxime and azelaic acid are not available, understanding their individual mechanisms can provide insights into their potential combined efficacy in dermatological applications.

Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, leading to cell lysis and death. It is effective against a broad spectrum of Gram-positive and Gram-negative bacteria, making it a valuable option for treating various bacterial skin infections. Its mechanism of action involves binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, disrupting cell wall synthesis and thereby exerting its bactericidal effects (Szmygin, 1996).

Azelaic Acid exhibits antimicrobial, anti-inflammatory, and comedolytic properties. It targets acne by reducing the proliferation of keratinocytes and inhibiting the growth of acne-causing bacteria such as *Propionibacterium acnes*. Azelaic acid's ability to reduce inflammation and normalize disordered skin cell growth contributes to its effectiveness in treating rosacea and hyperpigmentation, as well as acne (Schulte et al., 2015; Gollnick & Layton, 2008).

The **theoretical basis for synergy** between cefuroxime and azelaic acid lies in their complementary actions. Cefuroxime's broad-spectrum antibacterial activity can effectively reduce bacterial populations, while azelaic acid's anti-inflammatory and comedolytic effects can address the inflammatory aspects of dermatological conditions and prevent the formation of comedones. This combination could potentially offer a broader therapeutic effect, targeting both bacterial infections and inflammatory dermatoses more effectively than either agent alone.

ROLE IN COMBATING ANTIBIOTIC RESISTANCE

Mechanisms of Resistance Mitigation

Azelaic Acid has been identified as a valuable agent in the fight against antibiotic resistance, particularly in the context of acne treatment. Its mechanism of action does not directly contribute to antibiotic resistance, making it an effective alternative or adjunctive therapy in managing antibiotic-resistant Propionobacterium acnes strains. Farmery et al. (1994) demonstrated the in vitro activity of azelaic acid against antibiotic-resistant propionibacteria, suggesting its potential role in mitigating antibiotic resistance by providing an effective treatment option that does not exert selective pressure for resistance development.

Cefuroxime, as a second-generation cephalosporin, has a broad spectrum of activity that includes efficacy against bacteria that have developed resistance to first-generation cephalosporins. The use of cefuroxime in treating infections caused by resistant bacteria is supported by its ability to bind to and inhibit penicillin-binding proteins that have altered affinity for beta-lactam antibiotics. Chowers et al. (2022) discussed the impact of cefuroxime use on future collateral resistance, highlighting its role in a strategic antibiotic stewardship program to minimize the development of resistance.

Case Studies and Clinical Evidence

Clinical evidence supports the role of azelaic acid and cefuroxime in combating antibiotic resistance. Sardana et al. (2015) reviewed the worldwide scenario of antibiotic resistance to Propionobacterium acnes and discussed the management strategies, including the use of azelaic acid as a non-antibiotic alternative. This approach helps in reducing the reliance on antibiotics and, consequently, the pressure that selects for resistant strains.

In the context of cefuroxime, Pham et al. (2021) explored its intrinsic resistance mechanisms in Lactococcus lactis, providing insights into how understanding these mechanisms can inform the development of strategies to overcome resistance. Moreover, studies like those conducted by O. Abdellatif et al. (2022) evaluating antibiotic resistance patterns highlight the importance of monitoring resistance trends to guide the use of antibiotics like cefuroxime effectively.

ADVANTAGES OF CEFUROXIME-AZELAIC ACID COMBINATION THERAPY

Enhanced Efficacy in Treatment of Dermatological Conditions

Cefuroxime is known for its broad-spectrum antibacterial activity, making it effective against a wide range of bacteria that cause skin infections. Its ability to penetrate the skin and reach effective concentrations at the site of infection enhances its therapeutic potential in dermatology (Chowers et al., 2022).

Azelaic Acid has been demonstrated to be effective in treating acne and rosacea due to its antimicrobial, anti-inflammatory, and comedolytic properties. It reduces the growth of acne-causing bacteria and normalizes the disordered growth of skin cells, which can help in reducing inflammation and preventing the formation of comedones (Schulte et al., 2015).

The combination of these two agents could potentially offer a broader therapeutic effect by addressing both bacterial infections and inflammatory dermatoses more effectively than either agent alone.

Reduction in the Development of Resistance

Azelaic Acid's mechanism of action does not directly contribute to antibiotic resistance, making it an effective alternative or adjunctive therapy in managing antibiotic-resistant strains of bacteria. Its use alongside antibiotics could potentially reduce the selective pressure for the development of resistance, as it offers an effective treatment option that does not rely on antibiotic mechanisms (Farmery et al., 1994).

Cefuroxime's role in combating resistant bacteria further supports the combination's potential in reducing the development of resistance. By incorporating cefuroxime, which has a different mechanism of action from other commonly used antibiotics in dermatology, the combination therapy could help in diversifying the pharmacological approaches used in treatment, potentially slowing down the development of resistance (Pham et al., 2021).

Safety and Tolerability Profile

Both **cefuroxime** and **azelaic acid** have been reported to have good safety and tolerability profiles in their respective uses. Azelaic acid, in particular, is noted for its suitability for long-term use in chronic conditions like acne and rosacea, with minimal systemic absorption and side effects (Schulte et al., 2015). Cefuroxime's safety profile is well-established, with most adverse effects being mild and transient, making it suitable for use in a wide range of patients, including those with sensitive skin or predispositions to allergic reactions (Chowers et al., 2022).

CLINICAL APPLICATIONS AND GUIDELINES

Indications for Cefuroxime-Azelaic Acid Combination Therapy

Cefuroxime is indicated for the treatment of various bacterial infections, including those affecting the skin, such as impetigo, cellulitis, and wound infections. Its broad-spectrum activity makes it effective against a wide range of Gram-positive and Gram-negative bacteria (Chowers et al., 2022).

Azelaic Acid is indicated for the treatment of mild to moderate acne and rosacea. Its antimicrobial, anti-inflammatory, and comedolytic actions make it effective in reducing inflammatory lesions and hyperpigmentation associated with these conditions (Schulte et al., 2015).

The combination therapy could be indicated for complex dermatological conditions where bacterial infection is accompanied by inflammation, such as acne vulgaris with secondary infection, or in cases where there is a need to address both active infection and post-inflammatory hyperpigmentation or erythema.

Treatment Protocols and Dosage Recommendations

For **Cefuroxime**, the typical dosage for skin infections in adults is 250-500 mg twice daily, depending on the severity of the infection. The duration of therapy usually ranges from 7 to 10 days but may be adjusted based on the clinical response (Chowers et al., 2022).

Azelaic Acid is typically applied topically in a 15-20% cream or gel formulation. The recommended usage is twice daily, applied to the affected areas after cleansing. Improvement in symptoms is generally observed within 4 weeks of consistent use, with ongoing treatment recommended for maintaining benefits (Schulte et al., 2015).

Patient Selection and Management Strategies

Patient selection for the combination therapy should consider the individual's specific dermatological condition, the presence of bacterial infection, and the patient's history of antibiotic use to minimize the risk of resistance. It is also essential to consider the patient's skin type and any history of sensitivity or allergic reactions to components of the therapy (kumar, U., & Rawal, J., 2023).

Management strategies should include monitoring for signs of improvement or adverse reactions, adjusting the treatment regimen as necessary, and educating patients on the importance of adherence to the prescribed therapy. It is also crucial to implement strategies for minimizing antibiotic resistance, such as limiting the duration of antibiotic use to the shortest effective period and considering combination therapy only in cases where it offers clear benefits over monotherapy.

CHALLENGES AND LIMITATIONS

Potential Side Effects and Contraindications

Cefuroxime is generally well-tolerated, but like all antibiotics, it can cause side effects. Common adverse effects include gastrointestinal disturbances (nausea, vomiting, diarrhea), allergic reactions, and, less commonly, alterations in blood counts. Serious but rare side effects may include pseudomembranous colitis and severe allergic reactions. Cefuroxime should be used with caution in patients with a history of severe hypersensitivity to beta-lactam antibiotics (Chowers et al., 2022).

Azelaic Acid is also well-tolerated by most patients. The most common side effects are local and include pruritus, burning, stinging, and erythema. These symptoms are usually mild and often diminish with continued use. Azelaic acid is contraindicated in individuals with hypersensitivity to the formulation. Given its minimal systemic absorption, systemic side effects are rare (Schulte et al., 2015).

Limitations in Current Research and Future Perspectives

The **current research** on the use of cefuroxime and azelaic acid focuses on their individual effects, with limited studies exploring their combined use in dermatological therapy. This gap in the literature presents a challenge for clinicians considering this combination therapy, as there is a lack of specific guidelines on dosing, duration, and patient selection.

Future perspectives in this area could include clinical trials designed to evaluate the efficacy, safety, and tolerability of the combination of cefuroxime and azelaic acid in treating dermatological conditions. Such studies would help to establish evidence-based guidelines for the use of this combination therapy. Additionally, research into the mechanisms of action when these agents are used together could provide insights into potential synergistic effects or reduced resistance development.

DISCUSSION

Potential Benefits

The theoretical synergy between cefuroxime, a broad-spectrum antibiotic, and azelaic acid, with its antimicrobial, anti-inflammatory, and comedolytic properties, suggests a comprehensive approach to treating complex dermatological conditions. This combination could potentially offer enhanced efficacy against a wide range of dermatological conditions, including those with a bacterial component and inflammatory dermatoses like acne and rosacea. The dual action of targeting bacterial pathogens and reducing inflammation could provide a more effective treatment strategy than monotherapy, addressing both the causes and symptoms of dermatological conditions.

Moreover, the use of azelaic acid alongside cefuroxime may contribute to a reduction in the development of antibiotic resistance. Azelaic acid's mechanism of action does not contribute to antibiotic resistance, making it a valuable adjunct in the era of increasing resistance to conventional antibiotics.

Challenges and Limitations

Despite the potential benefits, there are significant challenges and limitations to consider. The primary challenge lies in the lack of direct clinical evidence supporting the combined use of these agents. Most available data pertain to their individual use, leaving a gap in knowledge regarding the optimal dosing, duration, and patient selection criteria for combination therapy.

Potential side effects and contraindications associated with each agent also warrant careful consideration. While both cefuroxime and azelaic acid are generally well-tolerated, the possibility of adverse reactions, particularly with long-term use, necessitates a cautious approach. Patient education and monitoring for side effects are crucial components of management strategies.

Future Perspectives

Addressing the current limitations in research is essential for advancing the use of cefuroxime and azelaic acid combination therapy in dermatology. Future clinical trials are needed to evaluate the safety, efficacy, and tolerability of this combination, with a focus on establishing evidence- based guidelines for its use. Research should also explore the mechanisms underlying the potential synergistic effects of these agents when used together.

Furthermore, studies on patient outcomes, including quality of life and satisfaction with treatment, could provide additional insights into the value of this combination therapy. Understanding patient experiences and preferences is vital for optimizing treatment strategies and ensuring adherence to therapy.

CONCLUSION

The combination of cefuroxime and azelaic acid presents a promising but underexplored approach to dermatological therapy. While theoretical benefits suggest its potential utility, the absence of direct clinical evidence highlights the need for further research. Future studies should aim to fill this gap, providing the data necessary to guide clinical practice and optimize outcomes for patients with dermatological conditions.

ACKNOWLEDGEMENT

We would like to express our sincere gratuide to everyone who contributed to the sucessful process Cefuroxime Azelaic Acid Combination in resisting antibiotic Resistance in Dermatology. Special thanks to our research and development team their trieless efforts and innovative approches. Finally, I would like thank my family and my Guide for their unwavering support and collaboration throughtout this project.

REFERENCES

1. Dallo, M., Patel, K., & Hebert, A. A. Topical antibiotic treatment in dermatology. *Antibiotics (Basel, Switzerland)*, 2023; *12*(2): 188. https://doi.org/10.3390/antibiotics12020188
2. Del Rosso, J. Q., Webster, G. F., Rosen, T., Thiboutot, D., Leyden, J. J., Gallo, R., Walker, C., Zhanel, G., & Eichenfield, L. Status report from the scientific panel on antibiotic use in dermatology of the American acne and Rosacea society: Part 1: Antibiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impact of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use. *The Journal of Clinical and Aesthetic Dermatology*, 2016; *9*(4): 18–24. https://www.ncbi.nlm.nih.gov/pubmed/27462384
3. MacGibeny, M. A., Jo, J.-H., & Kong, H. H. Antibiotic stewardship in dermatology-reducing the risk of prolonged antimicrobial resistance in skin. *JAMA Dermatology (Chicago, Ill.)*, 2022; *158*(9): 989–991. https://doi.org/10.1001/jamadermatol.2022.3168
4. Miller, A. C., Adjei, S., Temiz, L. A., Batta, S., & Tyring, S. K. Antibiotic resistance in dermatology part 2: Combating resistance. *Skin Therapy Letter*, 2023; *28*(2): 6–9.

https://www.ncbi.nlm.nih.gov/pubmed/37054726

5. Miller, A. C., Adjei, S., Temiz, L. A., & Tyring, S. K. Antibiotic resistance in dermatology part 1: Mechanisms of resistance. *Skin Therapy Letter*, 2023; *28*(1): 7–10. https://www.ncbi.nlm.nih.gov/pubmed/36657435
6. Shah, R. A., Hsu, J. I., Patel, R. R., Mui, U. N., & Tyring, S. K. Antibiotic resistance in dermatology: The scope of the problem and strategies to address it. *Journal of the American Academy of Dermatology*, 2022; *86*(6): 1337–1345. https://doi.org/10.1016/j.jaad.2021.09.024
7. Balfour, J. A., Bryson, H. M., & Brogden, R. N. Imipenem/cilastatin. *Drugs*, 1996; 51(1): 99–136. https://doi.org/10.2165/00003495-199651010-00008
8. Schulte, B. C., Wu, W., & Rosen, T. Azelaic acid: Evidence-based update on mechanism of action and clinical application. *Journal of Drugs in Dermatology: JDD*., 2015; 14(9): 964–968. https://www.ncbi.nlm.nih.gov/pubmed/26355614
9. Sauer, N., Oślizło, M., Brzostek, M., Wolska, J., Lubaszka, K., & Karłowicz-Bodalska, K. The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications. *Postepy Dermatologii i Alergologii*, 2023; 40(6): 716–724. https://doi.org/10.5114/ada.2023.133955
10. Shah, R. A., Hsu, J. I., Patel, R. R., Mui, U. N., & Tyring, S. K. Antibiotic resistance in dermatology: The scope of the problem and strategies to address it. *Journal of the American Academy of Dermatology*, 2022; 86(6): 1337–1345. https://doi.org/10.1016/j.jaad.2021.09.024
11. Congdon, S. T., Guaglione, J. A., Ricketts, O. M. A., Murphy, K. V., Anderson, M. G., Trowbridge, D. A., Al-Abduladheem, Y., Phillips, A. M., Beausoleil, A. M., Stanley, A. J., Becker, T. J., & Silver, A. C. Prevalence and antibiotic resistance of Staphylococcus aureus associated with a college-aged cohort: lifestyle factors that contribute to nasal carriage. *Frontiers in Cellular and Infection Microbiology*, 2023; *13*: 1195758. https://doi.org/10.3389/fcimb.2023.1195758
12. Elmonir, W., Essa, H., & El-Tras, W. Ecology of Staphylococcus aureus and its antibiotic resistance genes in dairy farms: Contributing factors and public health implications. *Slovenski Veterinarski Zbornik [Slovenian Veterinary Research]*, 2019; *56*(22). https://doi.org/10.26873/svr-815-2019
13. Kalu, C. F., Odimegwu, D. C., Kenechukwu, F. C., & Okore, V. C. Biochemical characteristics and antibiograms of Methicillin-Resistant Staphylococcus aureus and multi-drug Resistant Pseudomonas aeruginosa isolated from skin wounds of patients in a

tertiary-level hospital in Enugu, Nigeria. *Science View Journal*, 2023; *4*(1): 262–269. https://doi.org/10.55989/yoov9524

14. Lim, J. S., Park, H.-S., Cho, S., & Yoon, H.-S. Antibiotic susceptibility and treatment response in bacterial skin infection. *Annals of Dermatology*, 2018; *30*(2): 186–191. https://doi.org/10.5021/ad.2018.30.2.186
15. Mala, L., Lalouckova, K., & Skrivanova, E. Bacterial skin infections in livestock and plant-based alternatives to their antibiotic treatment. *Animals: An Open Access Journal from MDPI*, 2021; *11*(8): 2473. https://doi.org/10.3390/ani11082473
16. Gollnick, H., & Layton, A. Azelaic acid 15% gel in the treatment of rosacea. *Expert Opinion on Pharmacotherapy*, 2008; 9(15): 2699–2706. https://doi.org/10.1517/14656566.9.15.2699
17. Schulte, B. C., Wu, W., & Rosen, T. Azelaic acid: Evidence-based update on mechanism of action and clinical application. *Journal of Drugs in Dermatology: JDD*., 2015; 14(9): 964–968. https://www.ncbi.nlm.nih.gov/pubmed/26355614
18. Szmygin, K. The influence of selected antibiotics on the central action of aminophyllines--experimental studies. *Pneumonologia i alergologia polska*, 1996; 64(1): 63–69. https://www.ncbi.nlm.nih.gov/pubmed/9190241
19. Farmery, M., Jones', C., Eady, E., Cove, J., & Cunliffe, W. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. *The Journal of Dermatological Treatment*, 1994; 5(2): 63–65. https://doi.org/10.3109/09546639409084531
20. Sardana, K., Gupta, T., Garg, V. K., & Ghunawat, S. Antibiotic resistance to Propionobacterium acnes: worldwide scenario, diagnosis and management. *Expert Review of Anti-Infective Therapy*, 2015; 13(7): 883–896. https://doi.org/10.1586/14787210.2015.1040765
21. kumar, U., & Rawal, J. Biomarkers in Gastric Cancer: Pioneering Advances in Diagnosis, Personalized Treatment Strategies, and Screening for Improved Patient Prognosis. PEXACY International Journal of Pharmaceutical Science, 2023; 2(12): 167–185. 10.5281/zenodo.10314129
22. Chowers, M., Zehavi, T., Gottesman, B. S., Baraz, A., Nevo, D., & Obolski, U. Estimating the impact of cefuroxime versus cefazolin and amoxicillin/clavulanate use on future collateral resistance: a retrospective comparison. *The Journal of Antimicrobial Chemotherapy*, 2022; 77(7): 1992–1995. https://doi.org/10.1093/jac/dkac130
23. Pham, H. T., Shi, W., Xiang, Y., Foo, S. Y., Plan, M. R., Courtin, P., Chapot-Chartier,

M.-P., Smid, E. J., Liang, Z.-X., Marcellin, E., & Turner, M. S. Cyclic di-AMP oversight of counter-ion osmolyte pools impacts intrinsic cefuroxime resistance in Lactococcus lactis. *MBio*., 2021; 12(2). https://doi.org/10.1128/mBio.00324-21

24. O. Abdellatif, A., N. Ali, I., A. Mohamed, M., A. Ibrahim, M., & A. Mohamed, W. Evaluation of the antibiotic resistance pattern at the Medical Services Administration Hospital in Khartoum, Sudan, 2021. *Journal for Research in Applied Sciences and Biotechnology*, 2022; 1(4): 50–56. https://doi.org/10.55544/jrasb.1.4.6
25. Chowers, M., Zehavi, T., Gottesman, B. S., Baraz, A., Nevo, D., & Obolski, U. Estimating the impact of cefuroxime versus cefazolin and amoxicillin/clavulanate use on future collateral resistance: a retrospective comparison. *The Journal of Antimicrobial Chemotherapy*, 2022; 77(7): 1992–1995. https://doi.org/10.1093/jac/dkac130
26. Farmery, M., Jones', C., Eady, E., Cove, J., & Cunliffe, W. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. *The Journal of Dermatological Treatment*, 1994; 5(2): 63–65. https://doi.org/10.3109/09546639409084531
27. Pham, H. T., Shi, W., Xiang, Y., Foo, S. Y., Plan, M. R., Courtin, P., Chapot-Chartier, M.-P., Smid, E. J., Liang, Z.-X., Marcellin, E., & Turner, M. S. Cyclic di-AMP oversight of counter-ion osmolyte pools impacts intrinsic cefuroxime resistance in Lactococcus lactis. *MBio*., 2021; 12(2). https://doi.org/10.1128/mBio.00324-21
28. Schulte, B. C., Wu, W., & Rosen, T. Azelaic acid: Evidence-based update on mechanism of action and clinical application. *Journal of Drugs in Dermatology: JDD*., 2015; 14(9): 964–968. https://www.ncbi.nlm.nih.gov/pubmed/26355614
29. Chowers, M., Zehavi, T., Gottesman, B. S., Baraz, A., Nevo, D., & Obolski, U. Estimating the impact of cefuroxime versus cefazolin and amoxicillin/clavulanate use on future collateral resistance: a retrospective comparison. *The Journal of Antimicrobial Chemotherapy*, 2022; 77(7): 1992–1995. https://doi.org/10.1093/jac/dkac130
30. Schulte, B. C., Wu, W., & Rosen, T. Azelaic acid: Evidence-based update on mechanism of action and clinical application. *Journal of Drugs in Dermatology: JDD*., 2015; 14(9): 964–968. https://www.ncbi.nlm.nih.gov/pubmed/26355614